Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Juvenile myasthenia gravis (MG) is a rare form of MG, an autoimmune disorder of the neuromuscular junction resulting in ocular manifestations or generalized weakness, with onset before 18 years of age.
Biomarker and diagnostic research for juvenile myasthenia gravis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
2 clinical trials registered, 2 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
36 publications have been identified in PubMed for juvenile myasthenia gravis. Research spans Case Report / Case Series (33%), Review / Meta-Analysis (25%), and Epidemiology / Natural History (25%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 12 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 5:45 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries | 9 | 25% |
Disease patterns and progression | 9 | 25% |
Clinical study results | 3 | 8% |
Testing and diagnosis research | 2 | 6% |
Other research | 1 | 3% |
Kessi M (2026). [PMID: 41623245](https://pubmed.ncbi.nlm.nih.gov/41623245/). *Muscle Nerve*. [Epidemiology / Natural History]
Kortnoi P (2026). [PMID: 42115958](https://pubmed.ncbi.nlm.nih.gov/42115958/). *J Child Neurol*. [Diagnostic / Biomarker]
Ongun EA (2026). [PMID: 41936404](https://pubmed.ncbi.nlm.nih.gov/41936404/). *Ther Apher Dial*. [Clinical Trial Publication]
Garg M (2026). [PMID: 41817069](https://pubmed.ncbi.nlm.nih.gov/41817069/). *Neurol India*. [Epidemiology / Natural History]
Zhong X (2026). [PMID: 41772612](https://pubmed.ncbi.nlm.nih.gov/41772612/). *J Transl Med*. [Review / Meta-Analysis]
Chakrapani TL (2026). [PMID: 41490161](https://pubmed.ncbi.nlm.nih.gov/41490161/). *J Child Neurol*. [Diagnostic / Biomarker]
Fischer AF (2026). [PMID: 41870109](https://pubmed.ncbi.nlm.nih.gov/41870109/). *Int Ophthalmol Clin*. [Review / Meta-Analysis]
Lin J (2026). [PMID: 41795178](https://pubmed.ncbi.nlm.nih.gov/41795178/). *Muscle Nerve*. [Clinical Trial Publication]
Thomas N (2026). [PMID: 41328708](https://pubmed.ncbi.nlm.nih.gov/41328708/). *Diabetes Metab Res Rev*. [Review / Meta-Analysis]
Bardhan M (2026). [PMID: 32644361](https://pubmed.ncbi.nlm.nih.gov/32644361/). *Unknown Journal*. [Case Report / Case Series]
AI-curated news mentioning juvenile myasthenia gravis
Updated Mar 7, 2026
A multicenter retrospective study in China evaluates the use of efgartigimod for treating juvenile myasthenia gravis, providing insights into its effectiveness and safety profile. This research contributes to the growing body of evidence supporting efgartigimod's role in managing this rare neuromuscular disorder.